119 related articles for article (PubMed ID: 23379954)
21. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Gill DM; Agarwal N; Vaishampayan U
Am Soc Clin Oncol Educ Book; 2017; 37():319-329. PubMed ID: 28561652
[TBL] [Abstract][Full Text] [Related]
22. MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Sheng Y; Ng CP; Lourie R; Shah ET; He Y; Wong KY; Seim I; Oancea I; Morais C; Jeffery PL; Hooper J; Gobe GC; McGuckin MA
Int J Cancer; 2017 May; 140(10):2351-2363. PubMed ID: 28205224
[TBL] [Abstract][Full Text] [Related]
23. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
Nguyen TV; Sleiman M; Moriarty T; Herrick WG; Peyton SR
Biomaterials; 2014 Jul; 35(22):5749-59. PubMed ID: 24726537
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
26. Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma.
Fukata S; Inoue K; Kamada M; Kawada C; Furihata M; Ohtsuki Y; Shuin T
Cancer; 2005 Mar; 103(5):931-42. PubMed ID: 15685621
[TBL] [Abstract][Full Text] [Related]
27. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
Gao C; Peng FH; Peng LK
Neoplasma; 2014; 61(6):680-9. PubMed ID: 25150313
[TBL] [Abstract][Full Text] [Related]
28. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
29. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
30. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
Richey SL; Hutson TE
Cancer J; 2013; 19(4):307-10. PubMed ID: 23867511
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
32. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
33. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Edeline J; Mottier S; Vigneau C; Jouan F; Perrin C; Zerrouki S; Fergelot P; Patard JJ; Rioux-Leclercq N
Hum Pathol; 2012 Nov; 43(11):1982-90. PubMed ID: 22626276
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
Lin JC; Huang WP; Liu CL; Lee JJ; Liu TP; Ko WC; Huang YC; Hsu ML; Wu CH; Chen YJ
Transplantation; 2013 Mar; 95(6):791-800. PubMed ID: 23354299
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
Xu Z; Yang F; Wei D; Liu B; Chen C; Bao Y; Wu Z; Wu D; Tan H; Li J; Wang J; Liu J; Sun S; Qu L; Wang L
Oncogene; 2017 Apr; 36(14):1965-1977. PubMed ID: 27841868
[TBL] [Abstract][Full Text] [Related]
36. Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
Harada K; Miyake H; Kusuda Y; Fujisawa M
Clin Transl Oncol; 2014 Sep; 16(9):801-6. PubMed ID: 24356934
[TBL] [Abstract][Full Text] [Related]
37. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
[TBL] [Abstract][Full Text] [Related]
38. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Lachaier E; Louandre C; Godin C; Saidak Z; Baert M; Diouf M; Chauffert B; Galmiche A
Anticancer Res; 2014 Nov; 34(11):6417-22. PubMed ID: 25368241
[TBL] [Abstract][Full Text] [Related]
40. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
